Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 7875997. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will be available for one year.About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics aims to improve pati...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promising efficacy in metastatic melanoma Iovance BiotherapeuticsTicker: NASDAQ:IOVAPrice: $28.69Recommendation: Buy Sector News It is sad, but cancer is a pervasive illness that has affected 16% of the population of the world. In order […]